191602-60-5 Usage
General Description
4-(3-Bromo-4-methoxyphenyl)pyridine is a chemical compound with the molecular formula C12H9BrNO. It is a yellow solid that is commonly used as a building block in the synthesis of pharmaceuticals, agrochemicals, and materials science applications. 4-(3-Bromo-4-methoxyphenyl)pyridine is a substituted pyridine derivative with a bromine atom and a methoxy group attached to the phenyl ring. It is highly reactive and has been found to exhibit potential biological and pharmacological activities. 4-(3-Bromo-4-methoxyphenyl)pyridine is widely used in the research and development of various organic and medicinal compounds due to its versatile reactivity and structural properties.
Check Digit Verification of cas no
The CAS Registry Mumber 191602-60-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,1,6,0 and 2 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 191602-60:
(8*1)+(7*9)+(6*1)+(5*6)+(4*0)+(3*2)+(2*6)+(1*0)=125
125 % 10 = 5
So 191602-60-5 is a valid CAS Registry Number.
InChI:InChI=1/C12H10BrNO/c1-15-12-3-2-10(8-11(12)13)9-4-6-14-7-5-9/h2-8H,1H3
191602-60-5Relevant articles and documents
Large-scale Negishi coupling as applied to the synthesis of PDE472, an inhibitor of phosphodiesterase type 4D
Manley, Paul W.,Acemoglu, Murat,Marterer, Wolfgang,Pachinger, Werner
, p. 436 - 445 (2013/09/06)
5-[2-Methoxy-5-(4-pyridinyl)phenyl]-2,1,3-benzoxadiazole (PDE472) is a selective inhibitor of the phosphodiesterase PDE4D isoenzyme, which is a recognised drug target for the treatment of asthma. Different synthetic routes to PDE472 were investigated, and the research synthesis was optimised to prepare a phase I batch on pilot-plant scale with the focus on the elimination or minimization of inherent process risks. An important refinement of the key Negishi aryl-aryl coupling involved preforming the arylpalladium complex, which was then added to the arylzinc intermediate. Residual palladium was removed from PDE472 via crystallization of the hemi-maleate salt, which afforded drug-substance containing 2 ppm Pd.
